GILD
Stock Details
GILD is Gilead Sciences, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 63.34$. Average daily volumn in 3 months 6.84M. Market cap 81.54B
Stock symbol : GILD. Exchange : NasdaqGS. Currency : USD Lastest price : 65.06$. Total volume : 7.94M. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Gilead Sciences, Inc. (GILD)
Last Price
65.06$Change
2.74Volume
7.94M
| Previous Close | 62.32 |
| Open | 64.09 |
| Day Range | 63.60-65.27 |
| Bid | 65.12 x 900 |
| Ask | 65.12 x 900 |
| Volume | 7.94M |
| Average Volume | 6.84M |
| Market Cap | 81.54B |
| Beta | 0.33 |
| 52 Week Range | 57.17-74.12 |
| Trailing P/E | 19.89 |
| Foward P/E | 10.05 |
| Dividend (Yield %) | 4.69% |
| Ex-Dividend Date | 2022-09-14 |
Financial Details
Organization
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of li... ver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Market Cap:
81.54BRevenue:
27.3BTotal Assets:
67.95BTotal Cash:
5.34B
News about "Gilead Sciences, Inc."
Gilead stock rallies after J.P. Morgan turns bullish, citing HIV and undervalued oncology businesses
Source from : MarketWatch on MSN - 15 hours ago
Shares of Gilead Sciences Inc. rallied 3.2% in premarket trading Tuesday, after the biopharmaceutical company was upgraded at J.P. Morgan, which cited greater clarity on the human immunodeficiency ...See details»
Why This Gilead Analyst Believes The Stock Is Highly Undervalued
Source from : Benzinga.com on MSN - 10 hours ago
While there is increased visibility for Gilead Sciences, Inc’s (NASDAQ: GILD) HIV franchise, its emerging oncology franchise is not well reflected in its valuation, according to JPMorgan.See details»
Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 81%
Source from : YAHOO!Finance - 2 days ago
A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. And ...See details»
Gilead Lawsuit Takes Aim at Scheme, ‘Staggering in Scope,’ to Obtain, Re-sell HIV Drugs
Source from : Times of San Diego - 2 days ago
A federal judge has frozen the assets of dozens of people and entities accused of operating a nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc. HIV drugs. The widespread ...See details»
Unsealed Court Documents Reveal Scale of Counterfeit Gilead HIV Drugs Scam
Source from : IPWatchdog - 15 hours ago
The unsealed documents also included an asset freeze order against more than 60 defendants related to an anticounterfeiting suit filed last year by Gilead Sciences, Inc. Additionally, the court ...See details»
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by MAI Capital Management
Source from : Defense World - 4 days ago
MAI Capital Management grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 45.2% in the 2nd quarter, according to the company in its most recent 13F filing with the ...See details»
Gilead Sciences: Mother of Three Shares Her CAR T-Cell Therapy Journey: Kelly's Story
Source from : CSR Wire - 1 days ago
Kelly was getting ready to leave on a trip to celebrate her 25th wedding anniversary when she started experiencing pain in her abdomen and discovered a lump on her neck.See details»
Gilead Sciences widens battle against alleged counterfeit HIV drug ring
Source from : Daily - 3 days ago
Many counterfeit bottles contain antiviral pills manufactured by Gilead but illegally bought off the street and repackaged, while some have been found to contain other, potentially dangerous ...See details»
In the wake of Gilead Sciences, Inc.'s (NASDAQ:GILD) latest US$2.4b market cap drop, institutional owners may be forced to take severe actions
Source from : Yahoo - 6 days ago
To get a sense of who is truly in control of Gilead Sciences, Inc. (NASDAQ:GILD), it is important to understand the ownership structure of the business. And the group that holds the biggest piece ...See details»
Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production
Source from : Business Insider - 1 days ago
Biopharmaceutical company Kite, a Gilead Sciences, Inc. (GILD) company, announced Monday that the U.S. Food and Drug Administration ...See details»
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by NorthCrest Asset Manangement LLC
Source from : Defense World - 8 days ago
NorthCrest Asset Manangement LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 1.6% in the 2nd quarter, according to its most recent disclosure with the Securities and ...See details»
Gilead Sciences: WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
Source from : CSR Wire - 5 days ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline.See details»
Gilead Sciences Completes Acquisition of MiroBio
Source from : Yahoo - 14 days ago
FOSTER CITY, Calif., September 20, 2022--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio ...See details»
Gilead Sciences (GILD) Shares Cross Above 200 DMA
Source from : Nasdaq - 6 days ago
In trading on Wednesday, shares of Gilead Sciences Inc (Symbol: GILD) crossed above their 200 day moving average of $63.65, changing hands as high as $64.37 per share. Gilead Sciences Inc shares are ...See details»